GHRP-2 and GHRP-6 are among the oldest compounds in the growth hormone secretagogue category, and comparing them directly is useful because their differences illustrate how much variation exists even within a single closely related peptide family.
What They Are
Both are synthetic peptides that act on the ghrelin receptor to stimulate pituitary growth hormone release, developed and studied starting in the 1980s, predating newer, more selective compounds like ipamorelin. GHRP-6 is generally considered the more established and more extensively studied of the two in older literature, while GHRP-2 is often described as somewhat more potent for growth hormone release specifically.
Regulatory Status
Neither compound is FDA-approved for any use, and neither is eligible for pharmacy compounding as a stand-alone substance. Both are sold as research chemicals without an approved regulatory pathway in the U.S.
What the Research Shows
Both peptides have a reasonably substantial body of older academic research, including some human studies, examining growth hormone stimulation, given how long they've been studied relative to newer compounds in this category. GHRP-6 in particular has documented research showing it also stimulates appetite through a mechanism related to ghrelin's natural role in hunger signaling, a distinguishing effect from more selective compounds and one that's directly relevant to anyone considering it for body composition goals, since appetite stimulation works directly against a fat-loss objective.
Safety Considerations
Both compounds, consistent with their less selective receptor activity compared to newer GHRPs, are associated in the literature with more pronounced cortisol and prolactin elevation than compounds like ipamorelin. GHRP-6's appetite-stimulating effect, while interesting mechanistically, is also a practical consideration that can work against certain use goals. Neither has a modern, rigorous human safety trial program behind current commercial dosing protocols.
The Bottom Line
GHRP-2 and GHRP-6 illustrate how age and volume of research don't automatically mean a compound is better characterized for safety purposes, both have documented side-effect tendencies, less receptor selectivity and, for GHRP-6 specifically, appetite stimulation, that are actually clearer in the literature than for some less-studied alternatives, simply because they've been around long enough for those specific effects to be documented.
Why Age of Research Isn't the Same as Quality of Research
It's worth being direct about a pattern that recurs throughout this guide series: an older compound with decades of accumulated literature, like GHRP-6, isn't automatically better characterized than a newer one, since older studies often predate modern trial design standards, placebo controls, and blinding protocols discussed in this site's research section. A large volume of older, less rigorous research can create an impression of thorough validation that a closer look at individual study quality doesn't fully support.